Emergent BioSolutions (EBS) Receivables (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Receivables of $139.9 million for Q1 2026, down 40.37% year-over-year from $234.6 million in Q1 2025, and up 36.62% quarter-over-quarter from $102.4 million in Q4 2025.
Emergent BioSolutions (EBS) Receivables (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Receivables history runs 17 years deep, the most recent figure standing at $139.9 million for Q1 2026.
- In Q1 2026, Receivables fell 40.37% year-over-year to $139.9 million; the TTM figure through Mar 2026 stood at $139.9 million (down 40.37% YoY), while the FY2025 annual figure was $102.4 million, down 41.18% from the prior year.
- Receivables for Q1 2026 stood at $139.9 million, up from $102.4 million in the prior quarter.
- The five-year high for Receivables was $341.9 million in Q2 2023, with the low at $102.4 million in Q4 2025.
- The 5-year median for Receivables is $230.1 million (2022), against an average of $210.8 million.
- The sharpest annual moves came in 2023 and 2025: Receivables soared 51.59% in 2023, then tumbled 63.16% in 2025.
- Emergent BioSolutions' Receivables stood at $159.9 million in 2022, then jumped by 51.59% to $242.4 million in 2023, then dropped by 28.18% to $174.1 million in 2024, then slumped by 41.18% to $102.4 million in 2025, then soared by 36.62% to $139.9 million in 2026.
- Business Quant data shows EBS's Receivables at $139.9 million in Q1 2026, $102.4 million in Q4 2025, and $168.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 3.07 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 3.49 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 1.57 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 5.84 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 310.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 3.67 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 887.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.15 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 1.08 Bn |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 211.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 211.20 Mn |
| Mar 31, 2026 | 139.90 Mn |
| Dec 31, 2025 | 102.40 Mn |
| Sep 30, 2025 | 168.80 Mn |
| Jun 30, 2025 | 102.70 Mn |
| Mar 31, 2025 | 234.60 Mn |
| Dec 31, 2024 | 174.10 Mn |
| Sep 30, 2024 | 140.50 Mn |
| Jun 30, 2024 | 278.80 Mn |
| Mar 31, 2024 | 275.10 Mn |
| Dec 31, 2023 | 242.40 Mn |
| Sep 30, 2023 | 277.50 Mn |
| Jun 30, 2023 | 341.90 Mn |
| Mar 31, 2023 | 205.70 Mn |
| Dec 31, 2022 | 159.90 Mn |
| Sep 30, 2022 | 261.50 Mn |
| Jun 30, 2022 | 230.10 Mn |
| Mar 31, 2022 | 248.40 Mn |
| Dec 31, 2021 | 330.50 Mn |
| Sep 30, 2021 | 312.20 Mn |